Target Name: ZNF333
NCBI ID: G84449
Review Report on ZNF333 Target / Biomarker Content of Review Report on ZNF333 Target / Biomarker
ZNF333
Other Name(s): zinc finger protein 333 | Zinc finger protein 333 | ZN333_HUMAN | Zinc finger protein 333 (isoform 1) | Zinc finger protein 333, transcript variant 1 | ZNF333 variant 1

ZNF333: A Potential Drug Target and Biomarker for Autism

Introduction

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that affects millions of people worldwide, characterized by persistent patterns of social, communicative, and behavioral disturbances. Although the exact cause of ASD is still unknown, research has identified several genetic and non-genetic risk factors that contribute to its development. One of the non-genetic risk factors is the Zinc Finger Protein (ZFP) gene, which has been implicated in the development and progression of ASD. ZNF333, a specific variant of the ZFP gene, has been identified as a potential drug target and biomarker for ASD.

The ZNF333 Mutation

ZNF333 is a single-copy gene that encodes a zinc finger protein with 333 amino acid residues. The zinc finger is a common structural element in proteins that plays a crucial role in gene regulation and is involved in the regulation of various cellular processes. The ZNF333 gene has been studied extensively, and several studies have identified its association with various neurological disorders, including ASD.

The ZNF333 gene has four exons, and the last exon is a splice variants, which may result in different levels of gene expression. The ZNF333 gene has been implicated in the development and progression of ASD due to its association with various neurological disorders , such as Down syndrome, Fragile X syndrome, and hypoplasia of the brain.

Potential Drug Target

ZNF333 has been identified as a potential drug target for ASD due to its association with the neurotransmitter glutamate. Glutamic acid is an important neurotransmitter that is involved in many important neural function regulatory processes, including excitation, Movement and emotion regulation. ZNF333 has been shown to be involved in the regulation of glutamate levels in the brain, which may contribute to the symptoms of ASD.

Biomarker

ZNF333 has also been identified as a potential biomarker for ASD due to its association with the severity of symptoms. Studies have shown that higher levels of ZNF333 gene expression are associated with greater severity of symptoms in ASD patients, which may reflect increased levels of zinc finger protein.

Expression of ZNF333

ZNF333 has been shown to be expressed in various tissues and cell types, including brain, heart, and testes. The expression of ZNF333 has also been shown to be regulated by various factors, including DNA methylation.

Dietary Modification and ZNF333 Expression

Dietary modification, such as a high-zinc diet, has been shown to increase ZNF333 gene expression in rat brains, which may reflect increased levels of zinc finger protein. Furthermore, a study found that dietary supplementation with zinc-rich foods may also increase ZNF333 gene expression in human brains.

Conclusion

ZNF333 is a gene that has been identified as a potential drug target and biomarker for ASD. Its association with various neurological disorders and its involvement in the regulation of glutamate levels in the brain make it an attractive target for drug development. Additionally, its dietary modification may also play a role in increasing its expression levels, making it a valuable tool for the study of ASD.

Protein Name: Zinc Finger Protein 333

Functions: May be involved in transcriptional regulation

The "ZNF333 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF333 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486